A very useful tool is the online-accessible Metroticket calculator, which predicts the outcome of an individual patient with HCC considered for listing (expressed in 5-year survival and risk of HCC-related death after LT), starting from the radiology parameters and adapting the prediction to the variations in AFP and tumour morphology induced by locoregional therapy [25]. The gene discussed is AFP; the disease is hepatocellular carcinoma.